Tubercle Bacilli Binding to Host Cells: Vaccine Design

描述：(申请人提供)每年有300万人死于 结核病(TB)，尽管使用了现有的抗分枝杆菌药物 抗生素和卡介苗。显然，更好的疫苗和更好的方法 治疗结核病是必要的。这项沙田至新机场第一期可行性研究的目的是 评价结核分枝杆菌与几种人的结合作用 细胞类型和病原体识别分子。病原体通常会进入 通过使用细胞对细胞的识别和附着机制将其传递到宿主组织。 相反，先天免疫系统识别微生物中的许多常见模体。 细胞壁。这些基序存在于结核分枝杆菌和杆菌宿主中。 结合相互作用越来越多地被确定为结核分枝杆菌。这个 本研究的实验目的是对M。 结核与人类宿主分子和细胞的结合作用 更准确地模拟生理条件的剪切条件 阿龙。通过探索粘着事件，我们期待着新的发现 可用于开发更好的治疗方法或改进的分子靶点 疫苗。阻断这些靶点可能会通过取消最初的 结核分枝杆菌附着在允许的宿主细胞上。

DESCRIPTION: (Provided by Applicant) Three million people die each year from tuberculosis (TB) in spite of the use of the existing anti-mycobacterial antibiotics and the BCG vaccine. Clearly, a better vaccine and better ways to treat TB are needed. The purpose of this STTR Phase I feasibility study is to evaluate Mycobacterium tuberculosis-binding interactions with several human cell types and pathogen recognition molecules. Pathogens typically gain entry to a host tissue by using cell-to-cell recognition and attachment mechanisms. Conversely, the innate immune system recognizes many common motifs in microbial cell walls. These motifs are present in M. tuberculosis and bacilli-host binding interactions are increasingly being identified for M. tuberculosis. The experimental aim of the proposed study is to functionally evaluate M. tuberculosis binding interactions with human host molecules and cells under shear conditions that more accurately simulate physiological conditions in the lung. By exploring adhesion events we anticipate the discovery of novel molecular targets that could be used to develop better therapies or an improved vaccine. Blocking these targets may prevent infection by abrogating initial attachment by M. tuberculosis to permissive host cells.